BY ELIZABETH PFIESTER and JAMES ELLIOTT: Why does insulin cost so much to patients in the USA and around the world? Why is insulin, a widely sold drug of which most forms are now off-patent, so incredibly expensive? These are simple questions, but ones with a number of complicated answers. This post will break some of those answers down and point you in the direction further reading if you want to dive deeper.
1. Only 3 Companies Control 90% of the Global Insulin Market
The ‘big three’ insulin producers – Eli Lilly, Novo Nordisk and Sanofi – dominate more than 90% of the world insulin market by value. Often only one of these companies supplies insulin in a country, which means they more or less hold a monopoly there and can set prices as they wish. In some countries, notably China and India, there are domestic insulin companies that can help drive down the price. This means we need more companies in markets like the USA to help bring prices down. We’ll touch on that a bit further down the list. (read more)
BY ASHLEY WELCH: Staying active, eating a healthy diet andare hallmarks of a heart-healthy lifestyle, and new research suggests they may also have another benefit. Following the same guidelines that are good for your heart could also significantly reduce the risk of .
Every year, about 600,000 Americans die of, making it the leading cause of death in the U.S. for both men and women. And about 1 in 10 Americans have diabetes, with 90 to 95 percent of cases being type 2 diabetes, the Centers for Disease Control and Prevention reports.
Dr. Janette Nesheiwat says the two diseases are closely related. (read more)
BY ENDOCRINOLOGY ADVISOR: An improved genetic risk score for type 1 diabetes (T1D), called the T1D GRS2, signiﬁcantly improved identification of persons with T1D from those with type 2 diabetes (T2D) and may be useful in differentiating diabetes subtypes and predicting T1D in newborn screening studies, according to findings published in Diabetes Care.
T1D has a largely heritable component, but published genetic risk scores to date have not fully captured all information on risk for T1D at non-human leukocyte antigen (HLA) loci or at HLA risk loci. Researchers have developed a new T1D genetic risk score that incorporates HLA alleles and their interactions more completely and includes recently discovered non-HLA loci. (read more)
BY JULIE WORKMAN: As medical technology and research continues to make advancements, each new year brings about fresh developments and new opportunities for diabetes management. Research organizations like JDRF and Joslin Diabetes Center are improving our understanding of diabetes with the motivation of better management and, ultimately, the hope for a diabetes cure.
Staying informed and updated on the conversation within the world of diabetes is useful for doctors and people with diabetes, as well as families and care givers. Here’s a rundown of some research to keep an eye on this year. (read more)
BY BAILEY KING: Researchers announced Tuesday a major breakthrough in the search for a cure of Type 1 diabetes.
In a study published in Nature Cell Biology, researchers at University of California San Francisco said they have, for the first time, transformed human stem cells into mature insulin-producing cells, according to a press release.
Replacing these insulin-producing cells, which are lost in patients with Type 1 diabetes, has long been a dream of regenerative medicine, but until now, scientists didn’t know how to produce cells in a lab dish that work as they would in healthy adults. (read more)